Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.16 |
---|---|
High | 19.06 |
Low | 18.16 |
Bid | 19.11 |
Offer | 19.16 |
Previous close | 18.38 |
Average volume | 298.89 |
---|---|
Shares outstanding | 118.69m |
Free float | 111.55m |
P/E (TTM) | 40.02 |
Market cap | 2.53bn USD |
EPS (TTM) | 0.5335 USD |
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Announcements
- Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
- Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
- Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
- Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
- Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
- Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
More ▼